AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02723383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BACLOFEN
Description: Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
Study NCT02723383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
Study NCT02160470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy with Retrieval
Description: Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
Study NCT02160470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy with Compound Extinction
Description: Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
Study NCT02160470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy with Retrieval and Compound Extinction
Description: Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
Study NCT02160470 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-guided Exposure Therapy
Description: Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
Study NCT02271659 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy boost with external beam radiotherapy
Description: Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
Study NCT02271659 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Exclusive external beam radiotherapy
Description: Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
Study NCT00468858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilized, single dose vials and sterile water for~> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months
Study NCT00468858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-DEN-Post-Transfection F17
Description: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
Study NCT00468858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-DEN-Post-Transfection F19
Description: Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
Study NCT02274623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Capsules
Description: escalating doses
Study NCT00543101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir (DRV/r)
Description: Switch to DRV/r at a dose of 600/100 BID for 48 weeks
Study NCT00543101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continue on current dual boosted PI
Description: Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (\< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks
Study NCT03228953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic testing
Description: Pharmacogenomic testing is delivered to treating providers of patients with major depressive disorder
Study NCT03022383 — intervention group
Intervention type: DEVICE
Intervention: DRI OCT Triton plus
Description: OCT Machine used for diagnostic purposes
Study NCT03036150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg or 5 mg tablets given once daily, per oral use.
Study NCT03036150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching dapagliflozin 10 mg or 5 mg
Study NCT02357719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VistaO2 FLUX device
Description: Full night VistaO2 FLUX device monitoring synchronized with the gold standard polysomnography.
Study NCT06235853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood serum: sUPAR, PAI-1, IL-8.
Description: The concentration of described biomarkers were measured in serum.
Study NCT06235853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine: IL-8, APOE, VEGF.
Description: The concentration of described biomarkers were measured in urine.
Study NCT00843115 — intervention group
Intervention type: OTHER
Intervention: donepezil
Description: Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
Study NCT02773745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Prehab
Description: Pool therapy
Study NCT01618110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (Magstim, Rapid)
Description: Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.
Study NCT01618110 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo Treatment
Description: Sham coil (minimal magnetic field, same noise and feeling)
Study NCT03031041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided short-axis hydrodissection with 5cc normal saline
Description: Ultrasound-guided short-axis hydrodissection with 5cc normal saline between carpal tunnel and median nerve
Study NCT03031041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided long-axis hydrodissection with 3cc normal saline
Description: Ultrasound-guided long-axis hydrodissection with 3cc normal saline between carpal tunnel and median nerve
Study NCT04192656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive positive airway pressure
Description: non-invasive positive airway pressure is the first-line treatment for obstructive sleep apnea
Study NCT04192656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Hemisuccinate
Description: Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
Study NCT04192656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Hemisuccinate
Description: Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
Study NCT04192656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginaton
Description: ginnaton is ginkgo biloba extract
Study NCT04192656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginaton
Description: ginnaton is ginkgo biloba extract
Study NCT02100137 — intervention group
Intervention type: OTHER
Intervention: vaginal ultrasound
Description: vaginal ultrasound performed at a routine gyn examination
Study NCT02003963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Klub Kinect
Description: Dance Central and Just Dance are a series of rhythm games developed by Harmonix Music Systems exclusively for the Xbox 360 Kinect. The Dance Central suite of games (Dance Central 1, 2, and 3) and Just Dance will be played on the Xbox 360+ Kinect gaming console, which employs whole body movement using an infrared sensor that tracks body movements such that an external controller device is not required. The player performs dance moves demonstrated by on-screen characters and set to popular music, with a choice of over 650 dance moves, 90 dance routines, and over 300 songs.~The exergaming condition will wear a pedometer to record total steps during game play, and they will participate in private weigh-ins at each session to track body weight over the 12-week intervention.
Study NCT04291495 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ANDROSITOL®TEST
Description: Sperm incubation with ANDROSITOL®DGN and evaluation of sperm motility and mithocondrial membrane potential
Study NCT01108419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fermented dairy product
Study NCT01108419 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: milk-based non-fermented dairy product
Study NCT02237924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar
Description: Endostar 7.5mg / m2, 2 cycles of continuous intravenous pumping for ten days,and 2 cycles of maintenance therapy after radiotherapy
Study NCT02237924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDP
Description: DDP:100mg/m2 for 2-3 cycles
Study NCT02237924 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT:70-74Gy for 2-3 cycles
Study NCT02237924 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT:70-74Gy for 2-3 cycles
Study NCT01944670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal Joint Stabilizer - Elbow (IJS-E)
Description: Device designed for internal stabilization of the elbow
Study NCT02671734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video
Description: Short (2 minute 43 second), animated videos were designed addressing nature of the procedure, risks, benefits, and alternatives for upper and lower endoscopy respectively using PowToon (www.powtoon.com). Sixth grade language was used throughout the video. Videos were shown to youth and their parents on an iPad.
Study NCT05040620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olive Oil Topical Oil
Description: the effect of olive oil local application in decreasing orthodontic alighment phase
Study NCT03794505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Acetate
Description: depo-medrol 40 mg
Study NCT03794505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Acetate
Description: depo-medrol 40 mg
Study NCT03794505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: 2ml of 2% lidocaine
Study NCT03794505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine HCl Inj 7.5 MG/ML
Description: 25 mg
Study NCT04063657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External fixator
Description: Patients will be placed in an external fixator followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
Study NCT04063657 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Splinting
Description: Patients will be placed in a short leg splint followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
Study NCT03108937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in the experimental group will receive Dexmedetomidine during surgery.
Study NCT03108937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Patients in the control group will receive saline but not Dexmedetomidine during surgery.
Study NCT01306435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser
Description: 3-week treatment with three Laser sessions per week
Study NCT01306435 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: 3-week treatment with three Placebo Laser sessions per week
Study NCT04427488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morning Chronotype group
Description: Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
Study NCT04427488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evening Chronotype group
Description: Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
Study NCT01952080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide
Description: Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study
Study NCT02454374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee Loading protocol
Description: The clinician will review the patient at follow up appointments a further two to four times during the treatment period (dependent on symptom resolution/response), progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate (each participant will be asked to maintain a home treatment diary sheet). The physiotherapist will encourage compliance during the treatment period and beyond.
Study NCT02454374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physiotherapy Care
Description: Routine Physiotherapy Care
Study NCT01523210 — intervention group
Intervention type: OTHER
Intervention: physiotherapy
Description: thirty minutes passive flexion and extension of the elbow joint by a physiotherapist
Study NCT01786538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib/FOLFOX
Description: FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Regorafenib will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
Study NCT01786538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo/FOLFOX
Description: FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Placebo will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
Study NCT03725501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-L1023
Description: ALS-L1023 is an active fraction extracted from Melissa officinalis L. (Labiatae; lemon balm) leaves.
Study NCT03725501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: LUCENTIS® (an anti-neovascular VEGF-A inhibitor) 0.5 mg, intravitreal injection
Study NCT03725501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranibizumab
Description: LUCENTIS® (an anti-neovascular VEGF-A inhibitor) 0.5 mg, intravitreal injection
Study NCT03725501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group for comparison with oral administration of ALS-L1023
Study NCT01797133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ID fellow-based antibiotic pre-authorization
Description: All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.
Study NCT01797133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-based antibiotic pre-authorization
Description: All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.
Study NCT02953028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Auto-CPAP-machine for treating Obstructive Sleep Apnea With positive airway pressure
Study NCT02953028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Advancing Splint
Description: Oral Appliance for providing an open upper airway as a mean of treating Obstructive Sleep Apnea
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pevonedistat
Description: Administered each cycle on days 1, 3 and 5.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Administered each cycle on days 1, 3 and 5.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Administered each cycle on days 2, 9, 16 and 23.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Administered each cycle on days 2, 9, 16 and 23.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Taken orally each cycle on days 2 through 15.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken orally each cycle on days 2 through 15.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-asparaginase
Description: Administered via intramuscular injection (IM) each cycle on days 9 and 23.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: Administered via intramuscular injection (IM) each cycle on days 9 and 23.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Administered via IV each cycle on day 2.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered via IV each cycle on day 2.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Administered to all subjects via IT injection on day 1; and on days 9, 16, and 23 to CNS positive subjects.
Study NCT03349281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Administered to all subjects via IT injection on day 1; and on days 9, 16, and 23 to CNS positive subjects.
Study NCT01648478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: It is a hyperinsulinemic-euglycemic clamp.
Description: The hyperinsulinemic-euglycemic clamp includes three periods:~* A basal period (from T-30 to T0)~* The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)~* The infusion of glucose at variable rate (so as to maintain euglycemia)
Study NCT00566345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)
Description: Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
Study NCT00566345 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate buffered saline
Description: Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
Study NCT04427878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsies of subcutaneous adipose tissue
Description: Two 4mm punch biopsies of subcutaneous abdominal or thight adipose tissue
Study NCT02943642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-dmDT390-bisFv(UCHT1)
Description: anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
Study NCT02943642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.